8 three 398 2 Pts Pts P* 0? 2 0? 0.55 128?168 370 140?485 0.57 0?7 two 0?9 0.12 five.3?93 64.7 1.1?74 0.57 23?0 52 19?2 0.76 Min ax Median Min ax P* IM800 (N=73)Age (yrs)WBC(109/L)Basophils ( ) [N=143]Platelets (109/L)BM blasts ( ) [N=142]Sex 27 45 63 47 64 38 26 36 0.FemaleMaleHasford Threat Category 15 22 35 49 36 49 31 22 30 21 15 21 1.LowInter.HighPerformance Status 49 22 1 0 –1 –1 3 4 31 25 35 68 44 61 0.Br J Haematol. Author manuscript; offered in PMC 2015 January 01.30 42 0 —2 –58 37 52 42 34 48 0.50 two 3 three 4 0.UnknownPalpable SplenomegalyYesNoUnknownPalpable HepatomegalyPageYesNIH-PA Author ManuscriptDeininger et al.NIH-PA Author ManuscriptNIH-PA Author ManuscriptIM400 (N=72) Median 69 1 –5 -97 65 96 Min ax Median Min ax P*IM800 (N=73)NoDeininger et al.Unknown.Two-sided p-value from Wilcoxon test (continuous variables) or Fisher’s precise test (sex, organomegaly).NOTA-NHS ester Purity P-value from Pearson’s chi-square test for Hasford threat category and functionality status. Unknowns had been excluded from significance tests. Pts=patients.*NIH-PA Author ManuscriptPageNIH-PA Author ManuscriptNIH-PA Author ManuscriptBr J Haematol. Author manuscript; obtainable in PMC 2015 January 01.TableTreatment outcomes of 145 CML-CP patients by therapy arm.IM400 (N=72) Pts 59 63 four 5 N=49 33 N=45 N=53 67 52?0 35 85 71?four 0.040 N=41 7 4 5 six 2?four three 4 1?two 0.49 88 78?4 66 90 81?6 0.38 82 71?0 62 85 75?2 0.40 95 CI Pts 95 CI P* IM800 (N = 73)Comprehensive haematologic response (confirmed)Complete haematologic response (any)Resistant diseaseNot evaluableComplete cytogenetic responseMolecular response at 1 year **: 16 four four 9 2?1 ten 19 9?two 0.13 9 2?1 14 26 15?0 0.023 36 22?1 28 53 39?7 0.3-log reduce (MMR)4-log lower(MR4.0)four.5-log lower(MR4.five)*One-sided p-value from Fisher’s exact test for superior outcome inside the IM800 arm.Br J Haematol. Author manuscript; offered in PMC 2015 January 01.**Based on blood specimens collected 295?06 days immediately after randomization (if a patient’s molecular response was tested a lot more than after during that interval, only the outcome obtained closest to day 365 was integrated within this evaluation).NIH-PA Author ManuscriptDeininger et al. PageNIH-PA Author ManuscriptNIH-PA Author ManuscriptTableTreatment outcomes of 111 sufferers with CML-CP based on molecular response at three monthsIM400 10 (N=19) Pts 18 0 N=15 six N=10 1 0 0 0 0?1 3 11 2?9 0.38 0 0 0?4 10 29 15?six 0 0?1 3 11 2?9 0.38 0 0 0?4 14 40 24?eight 10 0?five 11 41 22?1 0.080 0 0 0?4 26 74 57?six 0.0001 0.020 0.074 N=27 N=9 N=35 40 16?eight 23 85 66?six 0.0038 3 50 12?eight 25 93 76?9 0.2126818-91-3 Chemscene 031 N=27 N=6 N=28 3 1 1 95 74?00 33 92 76?eight 0.PMID:22943596 83 9 82 48?eight 44 98 88?00 0.095 95 CI Pts 95 CI P* Pts 95 CI Pts 95 CI P* ten (N=36) ten (N=11) 10 (N=45) IMCHR**Not evaluableCCyR***MR at 1 year****3-log (MMR)4-log(MR4.0)4.5-log(MR4.five)*One-sided p-value for poorer outcome in sufferers with ten reduction in transcript at three months, based on Fisher’s precise test.**Includes 84 CHRs (40 IM400, 44 IM800) achieved on or just before collection of 3-month specimen.***All CCyRs were achieved following day 90 specimen collection, except 1 IM400 patient four with ten Reduction.Br J Haematol. Author manuscript; obtainable in PMC 2015 January 01.****Based on blood specimens collected 295?06 days after randomization (if a patient’s molecular response was tested far more than once during that interval, only the result obtained closest to day 365 was incorporated within this analys.